Plasma levels of mannan-binding lectin-associated serine proteases are increased in type 1 diabetes patients with insulin resistance
Clinical and Experimental Immunology · 2024
DOI: 10.1093/cei/uxad113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Noppadol Kietsiriroje und 5 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Mannose-Binding Lectin, Insulin Resistance. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Council.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Activation of the lectin pathway of the complement system, as demonstrated by elevated levels of mannan-binding lectin proteins (MBL), contributes to vascular pathology in type 1 diabetes (T1D). Vascular complications are greatest in T1D individuals with concomitant insulin resistance (IR), however, whether IR amplifies activiation of the lectin pathway in T1D is unknown. We pooled pretreatment data from two RCTs and performed a cross-sectional analysis on 46 T1D individuals. We employed estimated glucose disposal rate (eGDR), a validated IR surrogate with cut-points of: <5.1, 5.1–8.7, and > 8.7 mg/kg/min to determine IR status, with lower eGDR values conferring higher degrees of IR. Plasma levels of MBL-associated proteases (MASP-1, MASP-2, and MASP-3) and their regulatory protein MAp44 were compared among eGDR classifications. In a subset of 14 individuals, we assessed change in MASPs and MAp44 following improvement in IR. We found that MASP-1, MASP-2, MASP-3, and MAp44 levels increased in a stepwise fashion across eGDR thresholds with elevated MASPs and MAp44 levels conferring greater degrees of IR. In a subset of 14 patients, improvement in IR was associated with significant reductions in MASPs, but not MAp44, levels. In conclusion, IR in T1D amplifies levels of MASP-1/2/3 and their regulator MAp44, and improvement of IR normalizes MASP-1/2/3 levels. Given that elevated levels of these proteins contribute to vascular pathology, amplification of the lectin pathway of the complement system may offer mechanistic insight into the relationship between IR and vascular complications in T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
- Endocrinology and Metabolism Unit, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
- School of Nursing and Health Sciences, University of Sunderland, Sunderland, UK.
- Department of Internal Medicine, Charles University, Prague, Czech Republic.
- Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.
ORCID-Profile: Noppadol Kietsiriroje, Ramzi A Ajjan, Jan Brôz, Verena Schroeder, Matthew D Campbell
Förderung
- Medical Research Council
Zitieren
APA
Kietsiriroje, N., Scott, G. E., Ajjan, R. A., Brôz, J., Schroeder, V., & Campbell, M. D. (2024). Plasma levels of mannan-binding lectin-associated serine proteases are increased in type 1 diabetes patients with insulin resistance. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad113
Vancouver
Kietsiriroje N, Scott GE, Ajjan RA, Brôz J, Schroeder V, Campbell MD. Plasma levels of mannan-binding lectin-associated serine proteases are increased in type 1 diabetes patients with insulin resistance. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxad113
BibTeX
@article{Kietsiriroje2024,
author = {Kietsiriroje, Noppadol and Scott, Georgia E and Ajjan, Ramzi A and Brôz, Jan and Schroeder, Verena and Campbell, Matthew D},
title = {Plasma levels of mannan-binding lectin-associated serine proteases are increased in type 1 diabetes patients with insulin resistance},
journal = {Clinical and Experimental Immunology},
year = {2024},
doi = {10.1093/cei/uxad113}
}
EUVIMED